Publications - Page 36 sur 57 - RespiFIL - Filière de santé des maladies respiratoires rares

Voici les publications scientifiques relatives aux maladies respiratoires rares auxquelles les membres de la filière ont contribué, classées par groupes de pathologies (depuis juillet 2021).

Pneumopathies interstitielles diffuses (PID)
Targeting IL-5/5R for the treatment of idiopathic chronic eosinophilic pneumonia.

Delcros Q, Taillé C, Vallée A, Brun AL, Chenivesse C, Couture P, Daboussi S, Guilleminault L, Juster F, Kahn JE, Lefèvre G, Liozon E, Magnan A, Meireles S, Moulis G, Puech C, Tcherakian C, Traclet J, Uzunhan Y, Cottin V, Groh M; CEREO, OrphaLung, and CRISALIS Networks.

J Allergy Clin Immunol Pract. 2022 Dec 26:S2213-2198(22)01335-6.
Pneumopathies interstitielles diffuses (PID)
Criteria for Progressive Pulmonary Fibrosis: Getting the Horse Ready for the Cart.

Cottin V.

Am J Respir Crit Care Med. 2023 Jan 1;207(1):11-13.
Pneumopathies interstitielles diffuses (PID)
Clinical features and outcomes of patients with myositis associated-interstitial lung disease.

Karampitsakos T, Tzilas V, Papaioannou O, Chrysikos S, Vasarmidi E, Juge PA, Vizirianaki S, Bibaki E, Reppa A, Sidiropoulos P, Katsaras M, Sotiropoulou V, Tsiri P, Koulousousa E, Theochari E, Tsirikos G, Christopoulos I, Malakounidou E, Zarkadi E, Sampsonas F, Hillas G, Karageorgas T, Daoussis D, Kalogeropoulou C, Dimakou K, Tzanakis N, Borie R, Dieudé P, Antoniou K, Crestani B, Bouros D, Tzouvelekis A.

Front Med (Lausanne). 2023 Jan 9;9:1096203.
Pneumopathies interstitielles diffuses (PID)
Deciphering an isolated lung phenotype of NKX2-1 frameshift pathogenic variant.

Delestrain C, Aissat A, Nattes E, Gibertini I, Lacroze V, Simon S, Decrouy X, de Becdelièvre A, Fanen P, Epaud R.

Front Pediatr. 2023 Jan 17;10:978598.
Pneumopathies interstitielles diffuses (PID)
COVID-19 in patients with pulmonary alveolar proteinosis: a European multicentre study.

Papiris SA, Campo I, Mariani F, Kallieri M, Kolilekas L, Papaioannou AI, Gonca Chousein E, Cetinkaya E, Bonella F, Borie R, Kokosi M, Pickworth T, Molina-Molina M, Gasa M, Radzikowska E, Fijolek J, Jouneau S, Gomez E, McCarthy C, Bendstrup E, Piotrowski WJ, Pabary R, Hadchouel A, Coolen-Allou N, Alfaro T, Robalo Cordeiro C, Antonogiannaki EM, Tomos IP, Papakosta D, Kontakiotis T, Panagiotou P, Douros K, Schams A, Lettieri S, Papaevangelou V, Kanaka-Gantenbein C, Karakatsani A, Loukides S, Costabel U, Crestani B, Morgan C, Tazawa R, Bush A, Griese M, Manali ED.

ERJ Open Res. 2023 Jan 3;9(1):00199-2022.
Pneumopathies interstitielles diffuses (PID)
Long-term evolution of neuroendocrine cell hyperplasia of infancy: the FRENCHI findings.

Dervaux M, Thumerelle C, Fabre C, Abou-Taam R, Bihouee T, Brouard J, Clement A, Delacourt C, Delestrain C, Epaud R, Ghdifan S, Hadchouel A, Houdouin V, Labouret G, Perisson C, Reix P, Renoux MC, Troussier F, Weiss L, Mazenq J, Nathan N, Dubus JC.

Eur J Pediatr. 2023 Feb;182(2):949-956.
Fibrose pulmonaire - FPI
Study protocol of an international patient-led registry in patients with pulmonary fibrosis using online home monitoring: I-FILE.

Nakshbandi G, Moor CC, Antoniou K, Cottin V, Hoffmann-Vold AM, Koemans EA, Kreuter M, Molyneaux PL, Wuyts WA, Wijsenbeek MS.

BMC Pulm Med. 2023 Feb 2;23(1):51.
Pneumopathies interstitielles diffuses (PID)
Inherited pulmonary surfactant metabolism disorders in Argentina: Differences between patients with SFTPC and ABCA3 variants.

Balinotti JE, Mallie C, Maffey A, Colom A, Epaud R, de Becdelievre A, Fanen P, Delestrain C, Medín M, Teper A.

Pediatr Pulmonol. 2023 Feb;58(2):540-549.
Maladies pulmonaires chroniques liées à l’environnement
Nebulised liposomal amphotericin-B as maintenance therapy in allergic bronchopulmonary aspergillosis: a randomised, multicentre trial.

Godet C, Couturaud F, Marchand-Adam S, Pison C, Gagnadoux F, Blanchard E, Taillé C, Philippe B, Hirschi S, Andréjak C, Bourdin A, Chenivesse C, Dominique S, Bassinet L, Murris-Espin M, Rivière F, Garcia G, Caillaud D, Blanc FX, Goupil F, Bergeron A, Gondouin A, Frat JP, Flament T, Camara B, Priou P, Brun AL, Laurent F, Ragot S, Cadranel J; NebuLamB study group and GREPI network; Godet C, Couturaud F, Cadranel J, Frat JP, Brun AL, Laurent F, Marchand-Adam S, Pison C, Gagnadoux F, Blanchard E, Taillé C, Philippe B, Hirschi S, Andréjak C, Chenivesse C, Dominique S, Bassinet L, Murris-Espin M, Rivière F, Garcia G, Caillaud D, Blanc FX, Goupil F, Gondouin A, Flament T, Camara B, Priou P, Ragot S.

Eur Respir J. 2022 Jun 16;59(6):2102218.
Maladies pulmonaires chroniques liées à l’environnement
Reply to: Nebulised liposomal amphotericin-B: a promising strategy for preventing ABPA relapse.

Godet C, Cadranel J, Frat JP, Ragot S, Couturaud F.

Eur Respir J. 2022 Nov 24;60(5):2201678.

FILTRER :

Par mot clé

Par maladies

Réinitialiser les filtres

Targeting IL-5/5R for the treatment of idiopathic chronic eosinophilic pneumonia.

Criteria for Progressive Pulmonary Fibrosis: Getting the Horse Ready for the Cart.

Clinical features and outcomes of patients with myositis associated-interstitial lung disease.

Deciphering an isolated lung phenotype of NKX2-1 frameshift pathogenic variant.

COVID-19 in patients with pulmonary alveolar proteinosis: a European multicentre study.

Long-term evolution of neuroendocrine cell hyperplasia of infancy: the FRENCHI findings.

Study protocol of an international patient-led registry in patients with pulmonary fibrosis using online home monitoring: I-FILE.

Inherited pulmonary surfactant metabolism disorders in Argentina: Differences between patients with SFTPC and ABCA3 variants.

Nebulised liposomal amphotericin-B as maintenance therapy in allergic bronchopulmonary aspergillosis: a randomised, multicentre trial.

Reply to: Nebulised liposomal amphotericin-B: a promising strategy for preventing ABPA relapse.